BPC-157 vs TB-500: Which Recovery Peptide Should You Choose?

Frequently Asked Questions

Is BPC-157 or TB-500 more effective for tendon injuries?

BPC-157 is the stronger default for tendon injuries. Its localized action, Achilles tenotomy data in rodents, and community signal across athletic recovery populations all point to faster soft-tissue repair at a lower dose. TB-500 works systemically and shines for post-surgical or cardiac tissue repair, but the direct tendon data is thinner. If a 4-week BPC-157 cycle stalls on a chronic tendinopathy, adding TB-500 is the next step.

Can I stack BPC-157 and TB-500 safely?

Mechanistically yes, but no direct synergy RCTs exist. BPC-157 acts through growth factor and nitric oxide pathways. TB-500 acts through actin cytoskeleton remodeling. The two do not overlap. Most recovery-focused peptide users run the stack for 4-8 weeks around an acute injury or post-surgical window, then taper TB-500 first and keep BPC-157 for maintenance. Monitor for injection site reactions and anything unusual.

Which peptide has more human research?

TB-500 has more controlled human data, but most of it is in ophthalmology and cardiac indications, not musculoskeletal recovery. RegeneRx ran Phase 2 trials in corneal healing that showed 58% complete healing versus 28% placebo at 28 days. BPC-157 has essentially no published human trials. Its evidence base is rodent preclinical plus a decade of community reporting across tens of thousands of users.

Are BPC-157 and TB-500 legal?

Both are sold as research chemicals in most jurisdictions. Neither is an approved pharmaceutical for human use in the United States, EU, or UK. Both are banned by WADA with a 4-year first-offense penalty for competitive athletes. Legal status is gray-market, which means regulatory enforcement is inconsistent and product quality varies dramatically. Buy from suppliers who publish third-party purity testing for every batch.

How fast do BPC-157 and TB-500 work?

Both peptides report noticeable effects within 1-3 weeks at standard clinical doses. BPC-157 tends to show earlier subjective changes in gut-related symptoms (days rather than weeks) because of direct mucosal action. TB-500 tends to surface more slowly as systemic tissue remodeling takes longer to express. Full cycle benefit typically requires 4-8 weeks. If nothing has changed at 4 weeks, reconsider the dose, the source, or the diagnosis.

What are the main downsides of each peptide?

BPC-157's main downsides are zero published human RCTs, no long-term safety data, and gray-market source variability. TB-500's main downsides are higher cost, injection-only administration, and the theoretical cancer-acceleration risk tied to its angiogenesis mechanism. Neither peptide is appropriate for cancer patients, pregnancy, or users unwilling to source and reconstitute research chemicals. Both require medical supervision if underlying disease is present.

How should I cycle these peptides?

Standard BPC-157 cycles run 4-8 weeks at 250-500 mcg per day, followed by 2-4 weeks off. TB-500 cycles run 4-6 weeks at 2.5-5 mg per week, with most protocols front-loading 5 mg for the first two weeks then tapering. Do not run either peptide continuously past 12 weeks without a break. On-off cadence matters because long-term signaling downstream of VEGF and actin pathways has never been studied in humans.

What's the difference between BPC-157 acetate and arginine salt?

Acetate is the standard research form and is effective subcutaneously. Arginine salt is a stabilized oral form that survives gastric pH. If you want oral BPC-157, the arginine salt is mandatory. Acetate taken orally has effectively zero bioavailability. Dosing is equivalent gram-for-gram. Suppliers should clearly label which form they're selling. If they don't, that's a red flag.

How do I spot a low-quality peptide supplier?

Missing certificate of analysis. Generic 'lab tested' claims without attached HPLC documents. Prices far below the cohort median. No endotoxin data. Vague sourcing language. Refusal to state the synthesis origin. Shipping from a country you wouldn't order pharmaceuticals from. Inconsistent reconstitution or color on arrival. Any one of these is a flag. Two or more, walk away. A good supplier publishes the COA per batch, with a batch number you can match to your vial.

Can I take BPC-157 or TB-500 while on SSRIs or other prescription meds?

Neither peptide has documented drug-drug interactions in the published literature, but the literature is thin. Both can theoretically amplify bleeding risk with anticoagulants because of their angiogenic action. BPC-157 has rodent data suggesting interaction with the dopaminergic and serotonergic systems, which may compound effects of SSRIs or dopamine agonists. Talk to a prescribing clinician before stacking with any psychiatric or cardiovascular medication.

When should I give up on a cycle that isn't working?

Give it the full 4 weeks first. Most reliable responses surface between week 2 and week 4. If nothing has shifted on the targeted tissue or symptom by week 4 at the upper end of the clinical dose range, reassess before extending. Likely causes: low-purity product, wrong diagnosis, misplaced injection site, or a condition that isn't actually responsive to this mechanism. Do not double the dose to force a response. That's how side effects appear.

Do I need to reconstitute these peptides myself?

Yes, both ship as lyophilized powder and require reconstitution with bacteriostatic water before injection. Oral BPC-157 arginine salt in capsule form is the exception. Reconstitution introduces contamination risk if done carelessly. Use sterile technique, bacteriostatic water (not sterile saline), and alcohol-wipe the vial top. Store reconstituted peptide refrigerated and use within 30 days. If the solution cloudies, discard it.